A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer’s disease and other neudegenerative conditions. The corresponding study was published in ACS ...
Artificial intelligence is revolutionizing drug development, significantly reducing the time it takes to bring life-saving ...
ELRIG Drug Discovery 2025 recognizes BubbleFect, a lipid-free cell delivery system that utilizes phase separation peptides for non-viral gene therapy delivery.
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
SAN DIEGO, Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services ...
A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory ...
Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7 th Inflammasome Therapeutics Summit held ...
Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback